home / stock / pacb / pacb quote
Last: | $1.38 |
---|---|
Change Percent: | -0.74% |
Open: | $1.37 |
Close: | $1.38 |
High: | $1.42 |
Low: | $1.3 |
Volume: | 9,895,285 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.38 | $1.37 | $1.38 | $1.42 | $1.3 | 9,895,285 | 04-25-2024 |
$1.36 | $1.51 | $1.36 | $1.51 | $1.35 | 10,983,047 | 04-24-2024 |
$1.47 | $1.56 | $1.47 | $1.65 | $1.45 | 9,620,042 | 04-23-2024 |
$1.56 | $1.49 | $1.56 | $1.6 | $1.47 | 8,964,453 | 04-22-2024 |
$1.55 | $1.47 | $1.55 | $1.67 | $1.4303 | 16,879,745 | 04-19-2024 |
$1.46 | $1.39 | $1.46 | $1.505 | $1.29 | 18,742,356 | 04-18-2024 |
$1.4 | $1.5 | $1.4 | $1.5195 | $1.25 | 35,377,652 | 04-17-2024 |
$1.4 | $1.95 | $1.4 | $2.01 | $1.36 | 65,402,057 | 04-16-2024 |
$2.835 | $3.19 | $2.835 | $3.2 | $2.81 | 8,948,619 | 04-15-2024 |
$3.17 | $3.31 | $3.17 | $3.35 | $3.13 | 8,707,109 | 04-12-2024 |
$3.38 | $3.4 | $3.38 | $3.47 | $3.27 | 5,399,034 | 04-11-2024 |
$3.33 | $3.42 | $3.33 | $3.5 | $3.25 | 8,262,295 | 04-10-2024 |
$3.61 | $3.45 | $3.61 | $3.7 | $3.41 | 5,326,052 | 04-09-2024 |
$3.45 | $3.57 | $3.45 | $3.57 | $3.38 | 4,990,737 | 04-08-2024 |
$3.35 | $3.27 | $3.35 | $3.43 | $3.22 | 4,746,257 | 04-05-2024 |
$3.33 | $3.42 | $3.33 | $3.64 | $3.29 | 5,801,035 | 04-04-2024 |
$3.36 | $3.37 | $3.36 | $3.515 | $3.21 | 7,664,101 | 04-03-2024 |
$3.41 | $3.6 | $3.41 | $3.6 | $3.37 | 7,983,250 | 04-02-2024 |
$3.65 | $3.83 | $3.65 | $3.845 | $3.58 | 6,081,929 | 04-01-2024 |
$3.75 | $3.76 | $3.75 | $3.89 | $3.68 | 6,566,469 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pacific Biosciences of California Inc. Company Name:
PACB Stock Symbol:
NASDAQ Market:
2024-04-18 06:00:04 ET Matthew Sykes from Goldman Sachs issued a price target of $2.50 for PACB on 2024-04-18 04:31:00. The adjusted price target was set to $2.50. At the time of the announcement, PACB was trading at $1.4. The overall price target consensus is at $5.50 w...
Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results. The compan...
2024-04-17 09:15:03 ET Canaccord Genuity analyst issues BUY recommendation for PACB on April 17, 2024 07:10AM ET. The previous analyst recommendation was Buy. PACB was trading at $1.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...